MaxCyte, Inc. Receives Nasdaq Non-Compliance Notice for Minimum Bid Price Rule

Key Points:

• MaxCyte, Inc. (Nasdaq: MXCT) received a non-compliance notice from the Nasdaq Stock Market on March 16, 2026, due to its share price closing below \$1.00 for 30 consecutive trading days.
• This triggers Nasdaq Listing Rule 5450(a)(1), which requires companies listed on the Nasdaq Global Select Market to maintain a minimum bid price of \$1.00 per share.
• The company now faces a 180-calendar day period, expiring September 14, 2026, to regain compliance with the minimum bid price rule.
• MaxCyte’s common stock will continue to trade on the Nasdaq Global Select Market during this period, with the ticker symbol MXCT.
• If compliance is not regained, MaxCyte may apply to transfer its listing to the Nasdaq Capital Market, potentially securing an additional 180-day compliance period.
• If the company cannot cure the deficiency, its common stock could be subject to delisting from Nasdaq.
• There is no assurance that MaxCyte will be able to regain compliance or meet other Nasdaq listing requirements going forward.

Details and Shareholder Relevance:

• Immediate Impact: The notice has no immediate effect on the trading of MaxCyte’s shares. The stock remains listed and is still tradable on the Nasdaq Global Select Market.
• Compliance Options: To regain compliance, MaxCyte’s closing bid price must reach or exceed \$1.00 for at least 10 consecutive trading days before September 14, 2026.
• Potential Further Actions: If the company fails to comply by the initial deadline, it may transfer to the Nasdaq Capital Market, provided it meets other listing requirements (except for the minimum bid price). This would give MaxCyte another 180 calendar days to remedy the deficiency.
• Risk of Delisting: If Nasdaq determines MaxCyte cannot cure the deficiency or if it is not eligible for an additional compliance period, the company will receive a delisting notice. MaxCyte would then have the right to appeal, during which its shares would remain listed.
• Uncertainty and Share Price Risk: The company explicitly warns that there can be no assurance it will regain compliance or remain in line with all applicable Nasdaq listing rules. This introduces significant uncertainty and may put downward pressure on MaxCyte’s share price, as potential delisting can affect liquidity, investor perception, and index inclusion.

Other Corporate Details:

• The company’s principal executive offices are located at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.
• The company’s telephone number is (301) 944-1700.
• MaxCyte is classified as an “emerging growth company” under SEC rules.
• This Form 8-K was signed by Douglas Swirsky, Chief Financial Officer, on March 20, 2026.

Why This Matters for Investors:

• Price Sensitive Event: Receipt of a Nasdaq non-compliance notice is a material event that can significantly affect share value. It signals risk concerning the company’s ability to maintain its public market listing.
• Potential for Increased Volatility: The uncertainty regarding MaxCyte’s ability to regain compliance could result in increased share price volatility and may impact investor confidence.
• Liquidity Concerns: Delisting from Nasdaq could reduce the liquidity of MaxCyte shares, making it more difficult for shareholders to buy or sell their positions and possibly forcing institutional investors to divest due to index or mandate constraints.
• Future Corporate Actions: MaxCyte may consider options such as a reverse stock split to increase its share price and regain compliance, though no such plans have been announced in this filing.

Disclaimer: This article summarizes information disclosed by MaxCyte, Inc. in its Form 8-K filing dated March 20, 2026. The information is intended for informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. Investors should conduct their own due diligence or consult with a financial advisor before making investment decisions based on this information. The author does not hold any position in MaxCyte, Inc. at the time of publication.

View MAXCYTE, INC. Historical chart here